| 000 | 01795 a2200505 4500 | ||
|---|---|---|---|
| 005 | 20250515115104.0 | ||
| 264 | 0 | _c20080715 | |
| 008 | 200807s 0 0 eng d | ||
| 022 | _a1464-3405 | ||
| 024 | 7 |
_a10.1016/j.bmcl.2008.03.072 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aGillespie, Roger J | |
| 245 | 0 | 0 |
_aAntagonists of the human adenosine A2A receptor. Part 3: Design and synthesis of pyrazolo[3,4-d]pyrimidines, pyrrolo[2,3-d]pyrimidines and 6-arylpurines. _h[electronic resource] |
| 260 |
_bBioorganic & medicinal chemistry letters _cMay 2008 |
||
| 300 |
_a2924-9 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article | ||
| 650 | 0 | 4 | _aAdenosine A1 Receptor Antagonists |
| 650 | 0 | 4 | _aAdenosine A2 Receptor Antagonists |
| 650 | 0 | 4 |
_aAntiparkinson Agents _xchemical synthesis |
| 650 | 0 | 4 | _aDrug Design |
| 650 | 0 | 4 | _aHumans |
| 650 | 0 | 4 | _aModels, Chemical |
| 650 | 0 | 4 |
_aParkinsonian Disorders _xdrug therapy |
| 650 | 0 | 4 |
_aPurines _xchemical synthesis |
| 650 | 0 | 4 |
_aPyrazoles _xchemical synthesis |
| 650 | 0 | 4 |
_aPyrimidines _xchemical synthesis |
| 650 | 0 | 4 | _aStereoisomerism |
| 650 | 0 | 4 | _aStructure-Activity Relationship |
| 700 | 1 | _aCliffe, Ian A | |
| 700 | 1 | _aDawson, Claire E | |
| 700 | 1 | _aDourish, Colin T | |
| 700 | 1 | _aGaur, Suneel | |
| 700 | 1 | _aJordan, Allan M | |
| 700 | 1 | _aKnight, Antony R | |
| 700 | 1 | _aLerpiniere, Joanne | |
| 700 | 1 | _aMisra, Anil | |
| 700 | 1 | _aPratt, Robert M | |
| 700 | 1 | _aRoffey, Jonathan | |
| 700 | 1 | _aStratton, Gemma C | |
| 700 | 1 | _aUpton, Rebecca | |
| 700 | 1 | _aWeiss, Scott M | |
| 700 | 1 | _aWilliamson, Douglas S | |
| 773 | 0 |
_tBioorganic & medicinal chemistry letters _gvol. 18 _gno. 9 _gp. 2924-9 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1016/j.bmcl.2008.03.072 _zAvailable from publisher's website |
| 999 |
_c17909208 _d17909208 |
||